It’s a remarkable story of recovery, but it’s unclear how useful this sort of therapy could become.
The background: Isabelle Holdaway had been given less than a 1% chance of survival after a lung transplant, carried out to combat the symptoms of cystic fibrosis, left her with an antibiotic-resistant infection. She had been sent home and was in a terrible physical condition: underweight, with liver failure, and with lesions on her skin from the infection.
A breakthrough: Her consultant at Great Ormond Street Hospital in London worked with a team at the University of Pittsburgh to develop an untested phage therapy. This treatment used a cocktail of three phages, which are viruses that solely attack and kill bacteria. Two of the three phages, selected from a library of more more than 10,000 kept at the University of Pittsburgh, had been genetically engineered to be better at attacking the bacteria. The therapy was injected into her bloodstream twice daily and applied to the lesions on her skin, according to Nature Medicine.
Now: Holdaway is not fully cured, but her infection is under control. Virtually all her lesions have cleared. She is still having twice-daily injections of the therapy, and her treatment team is planning to add a fourth phage to try to clear her of the infection entirely.
The promise: Antibiotic resistance is a growing emergency, and phage therapy is being held up as a potential treatment for antibiotic-resistant superbugs. It’s a promising avenue, but it’s a deeply personalized form of therapy, and we must be careful extrapolating too much from this single case study alone, which was not a full clinical trial.
Sign up here to get your dose of the latest must-read news from the world of emerging tech in our daily newsletter The Download.
